Clinical trial
Extension Study of ACTIQ Treatment for Children and Adolescents With…
NCT00236093 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00236093 |
|---|---|
| Title | Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain |
| Official title | A 4-week, Open-Label Extension Study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain, Cancer, Sickle Cell Anemia, Severe Burns |
| Intervention type | Drug |
| Interventions | ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | May 9, 2014 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: